WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 412715
CAS#: 15639-50-6
Description: Safingol is a lyso-sphingolipid protein kinase inhibitor. It has the molecular formula C₁₈H₃₉NO₂ and is a colorless solid. Medicinally, safingol has demonstrated promising anticancer potential as a modulator of multi-drug resistance and as an inducer of necrosis.
MedKoo Cat#: 412715
Name: Safingol
CAS#: 15639-50-6
Chemical Formula: C18H39NO2
Exact Mass: 301.2981
Molecular Weight: 301.52
Elemental Analysis: C, 71.70; H, 13.04; N, 4.65; O, 10.61
Synonym: Safingol; L-threo-dihydrosphingosine (d18:0) z
IUPAC/Chemical Name: (2S,3S)-2-aminooctadecane-1,3-diol
InChi Key: OTKJDMGTUTTYMP-ROUUACIJSA-N
InChi Code: InChI=1S/C18H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h17-18,20-21H,2-16,19H2,1H3/t17-,18-/m0/s1
SMILES Code: CCCCCCCCCCCCCCC[C@@](O)([H])[C@@]([H])(N)CO
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 301.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Coward J, Ambrosini G, Musi E, Truman JP, Haimovitz-Friedman A, Allegood JC, Wang E, Merrill AH Jr, Schwartz GK. Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy. 2009 Feb;5(2):184-93. doi: 10.4161/auto.5.2.7361. Epub 2009 Feb 6. PMID: 19098447.
2: Hamada M, Wakabayashi K, Masui A, Iwai S, Imai T, Yura Y. Involvement of hydrogen peroxide in safingol-induced endonuclease G-mediated apoptosis of squamous cell carcinoma cells. Int J Mol Sci. 2014 Feb 17;15(2):2660-71. doi: 10.3390/ijms15022660. PMID: 24549171; PMCID: PMC3958874.
3: Morales PR, Dillehay DL, Moody SJ, Pallas DC, Pruett S, Allgood JC, Symolon H, Merrill AH Jr. Safingol toxicology after oral administration to TRAMP mice: demonstration of safingol uptake and metabolism by N-acylation and N-methylation. Drug Chem Toxicol. 2007;30(3):197-216. doi: 10.1080/01480540701375018. PMID: 17613006.
4: Cho HE, Maurer BJ, Reynolds CP, Kang MH. Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Apr 1;1112:16-23. doi: 10.1016/j.jchromb.2019.02.023. Epub 2019 Feb 22. PMID: 30836314; PMCID: PMC6428217.
5: Ling LU, Tan KB, Lin H, Chiu GN. The role of reactive oxygen species and autophagy in safingol-induced cell death. Cell Death Dis. 2011 Mar 10;2(3):e129. doi: 10.1038/cddis.2011.12. PMID: 21390063; PMCID: PMC3101809.
6: Schwartz GK, Ward D, Saltz L, Casper ES, Spiess T, Mullen E, Woodworth J, Venuti R, Zervos P, Storniolo AM, Kelsen DP. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res. 1997 Apr;3(4):537-43. PMID: 9815717.
7: Dragusin M, Gurgui C, Schwarzmann G, Hoernschemeyer J, van Echten-Deckert G. Metabolism of the unnatural anticancer lipid safingol, L-threo- dihydrosphingosine, in cultured cells. J Lipid Res. 2003 Sep;44(9):1772-9. doi: 10.1194/jlr.M300160-JLR200. Epub 2003 Jun 1. PMID: 12777464.
8: Kelly R. Expression of concern: A general and concise asymmetric synthesis of sphingosine, safingol and phytosphingosines via tethered aminohydroxylation. Org Biomol Chem. 2017 Jul 21;15(27):5851. doi: 10.1039/c7ob90105d. Epub 2017 Jun 29. PMID: 28661539.
9: Tan KB, Ling LU, Bunte RM, Chng WJ, Chiu GN. In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia. J Control Release. 2012 Jun 10;160(2):290-8. doi: 10.1016/j.jconrel.2011.11.002. Epub 2011 Nov 10. PMID: 22100388.
10: Gantner ML, Eade K, Wallace M, Handzlik MK, Fallon R, Trombley J, Bonelli R, Giles S, Harkins-Perry S, Heeren TFC, Sauer L, Ideguchi Y, Baldini M, Scheppke L, Dorrell MI, Kitano M, Hart BJ, Cai C, Nagasaki T, Badur MG, Okada M, Woods SM, Egan C, Gillies M, Guymer R, Eichler F, Bahlo M, Fruttiger M, Allikmets R, Bernstein PS, Metallo CM, Friedlander M. Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy. N Engl J Med. 2019 Oct 10;381(15):1422-1433. doi: 10.1056/NEJMoa1815111. Epub 2019 Sep 11. PMID: 31509666; PMCID: PMC7685488.
